What weight loss can you expect in the first 12 weeks on Wegovy?

Why does 12 weeks fall at such an awkward point in the Wegovy schedule?

The licensed titration pathway for Wegovy starts at 0.25mg and steps up roughly every four weeks: 0.25mg, then 0.5mg, then 1mg, then 1.7mg, and finally the 2.4mg maintenance dose. Twelve weeks in, you are most likely on 1mg, still two dose increases away from the level at which the largest clinical results were measured. That does not make week 12 unimportant; it means the medicine is working exactly as it is designed to work.

The gradual escalation exists primarily to give your digestive system time to adjust. Jumping straight to a high dose produces far more nausea and vomiting, and the NHS semaglutide medicines page is clear that GI side effects are the most common reason people struggle early on. The slow ramp is a feature, not a flaw. Our page on how Wegovy weight loss progresses week by week maps this escalation in more detail if you want to track where you are in the schedule.

Appetite suppression does begin early, sometimes within the first week or two, because semaglutide starts activating GLP-1 receptors as soon as it is in your system. But the degree of suppression is dose-dependent, which is why the 12-week point is often described by our prescribers as the beginning of the journey rather than its destination. Progress at this stage is real. It just tends to accelerate later.

What do the numbers actually look like at 12 weeks, and how should you read them?

Clinical trial data does not break out a clean 12-week figure in the way that some people hope to find. The STEP 1 trial reported outcomes at 68 weeks, and interim analyses tend to cluster around the 20-week and 52-week marks. What the data does show is that by weeks 16–20, when most participants had reached or were approaching the 2.4mg dose, the average weight loss was tracking towards the region of 8–10% of starting body weight, with a long tail of further loss to come. You can find a fuller breakdown on our Wegovy weight loss results page.

At 12 weeks specifically, a reasonable expectation based on the trial trajectory is somewhere in the range of 3–6% of starting body weight, though this varies significantly. Some people lose more; a meaningful number lose less and go on to achieve strong results by month six. If you feel like you have barely moved at 12 weeks, that experience is genuinely common and does not predict your outcome at month nine. Our page on what to do if you are not losing weight on Wegovy addresses early stalls in detail, including when it is worth talking to your prescriber.

One thing worth keeping in mind: body weight fluctuates day to day by a kilo or more for ordinary reasons, hydration, digestion, hormonal changes. Weighing at the same time, in the same conditions, once a week is a more useful signal than daily weigh-ins that can quietly undermine your confidence.

What else is typically happening to your body during this period?

Weight on the scales is not the only thing shifting at 12 weeks. Many people report that their relationship with food has changed more noticeably than the number suggests. Portion sizes feel different. Cravings that were previously persistent become quieter. That psychological shift is part of how semaglutide works, it does not just slow gastric emptying and signal fullness; it also appears to reduce the reward salience of high-calorie foods in the brain.

The most common side effects during the first 12 weeks are gastrointestinal: nausea, occasional vomiting, loose stools or constipation, and a tendency towards burping or reflux. These tend to be most pronounced in the days after a dose increase and usually settle within a week or so. If you are curious about what Wegovy can achieve by the six-week mark, that context can help you understand how early changes fit into the broader pattern of side effects and progress over time. Our Wegovy overview covers the full side-effect picture, including the signs that warrant a call to your prescriber rather than a wait-and-see approach.

If you are wondering about the longer-term cost of staying on treatment, our Wegovy price page sets out how private prescription costs are structured in the UK, including what a legitimate price should cover.

How does the 12-week point feed into a decision about continuing?

Under NICE's appraisal of semaglutide (TA875), clinical guidance suggests reviewing whether to continue if someone has not achieved at least 5% weight loss after six months at the maintenance dose. Week 12 is not that review point, you are not yet at the maintenance dose and the clock on that six-month assessment has not really started. So if someone tells you to judge Wegovy's effectiveness at week 12, they are applying the wrong timeframe.

That said, 12 weeks is not too early to raise concerns with a prescriber. If side effects are unmanageable, if the dose increases are not going to plan, or if something in your health picture has changed, those are conversations worth having promptly. At nume, every repeat order goes through a fresh clinical review, a real prescriber reads your update before the next pen is dispensed. If you want to understand how that process works or check your own eligibility, speaking to our prescribers is a straightforward next step with no commitment to proceed.